Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.70 |
| ▸ | CLK1 | P49759 | 3/20 | 0.70 |
| ▸ | CLK2 | P49760 | 2/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | ACP1 | P24666 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651697 | 0.87 | DYRK1A (0.54) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL3654446 | 0.85 | DYRK1A (0.52) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL18743019 | 0.83 | WNT3A (0.56) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL23396975 | 0.81 | DYRK1A (0.48) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL3647596 | 0.80 | DKK1 (0.72) | CLK4DYRK1ADYRK1BMAPTSMN1; SMN2 | |
| SCHEMBL3650785 | 0.80 | GSK3B (0.47) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL3645314 | 0.79 | CDK2 (0.70) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL3644727 | 0.78 | DKK1 (0.50) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL5092092 | 0.78 | CLK4 (0.69) | CLK4DYRK1ADYRK1BCLK1CLK2 | |
| SCHEMBL3647860 | 0.77 | CCNT1 (0.47) | CLK4DYRK1ADYRK1BCLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190824-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | Wyeth a Corporation of the State of Delaware (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | claimed |
| EP-2190824-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | Wyeth a Corporation of the State of Delaware (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | CLK4 1921/4885DYRK1A 3212/4885DYRK1B 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.